Related Experiment Videos
Kringle 5 peptide-albumin conjugates with anti-migratory activity
Roger Léger1, Corinne Benquet, Xicai Huang
1Research Department, ConjuChem Inc., 225 President-Kennedy Ave., Suite 3950, Montréal, QC, H2X 3Y8 Canada. leger@conjuchem.com
Bioorganic & Medicinal Chemistry Letters
|March 12, 2004
Summary
Researchers investigated plasminogen peptide fragments conjugated to human serum albumin for anti-migratory effects. The N-terminus derivative of a specific kringle 5 segment showed significant inhibition of endothelial cell migration.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Biology
Background:
- Plasminogen kringle domains are implicated in various biological processes.
- Endothelial cell migration is crucial for angiogenesis and vascular repair.
- Human serum albumin (HSA) is a versatile carrier protein for drug delivery.
Purpose of the Study:
- To synthesize and evaluate peptide fragments of plasminogen's kringle 5 region conjugated to HSA.
- To assess the anti-migratory activity of these conjugates using a HUVEC migration assay.
- To determine the plasma stability of the modified HSA conjugates.
Main Methods:
- Synthesis of N- and C-terminus maleimido derivatives of three kringle 5 peptide fragments.
- Conjugation of peptide derivatives to Cys34 of human serum albumin.
- In vitro evaluation using human umbilical vein endothelial cell (HUVEC) migration assay.
- Assessment of plasma stability.
Main Results:
- One N-terminus maleimido derivative (residues 64-74 of kringle 5) conjugated to HSA exhibited potent anti-migratory activity.
- The anti-migratory effect was observed in the HUVEC migration assay.
- Plasma stability data was collected for the evaluated conjugates.
Conclusions:
- Specific peptide fragments of plasminogen kringle 5, when conjugated to HSA, can inhibit endothelial cell migration.
- The N-terminus maleimido derivative of the 64-74 segment of kringle 5-HSA conjugate is a promising candidate for further investigation.
- This approach offers potential for developing novel therapeutics targeting angiogenesis-dependent processes.